macro

Silgan Q3 2026: sales edge up 1.6% as profit slips 7.3%

Silgan's Q3 2026 net sales rose 1.6% to $2.04B while net income fell 7.3% to $104.98M, according to a 10-Q summary published by TradingView.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Silgan's third-quarter net sales climbed 1.6% from a year earlier to $2.04B, according to a 10-Q summary published by TradingView. Net income, however, dropped 7.3% to $104.98M from $113.29M, and diluted earnings per share fell to $0.99 from $1.06.

The top line was supported by passing higher raw-material and production costs on to customers, along with a more profitable mix in custom containers. Still, lower shipment volumes, a weaker product mix in other segments, higher restructuring and corporate development expenses, and reduced manufacturing efficiency in the dispensing business pulled operating income down.

Dispensing and specialty closures grew sales by 1.3% with flat unit volumes. Metal containers posted a 1.4% sales increase even though units fell about 4%, while custom containers rose 4.2% on pricing and mix despite volumes down roughly 8%. The company also expects its proposed Trivium acquisition to close around mid-2027, subject to regulatory approvals.

why it matters

For investors, profit trends matter more than revenue here: price pass-through lifted sales but did not offset falling volumes and tighter margins. The Trivium deal remains a 2027 factor whose timing depends on regulators.

market impact

Silgan Holdings: sales growth did not offset lower profit, a mild negative for the stock

  • Silgan Holdings shares pressure down — net income and EPS fell on weaker volumes and higher operating costs

tags

instruments

Silgan HoldingsSLGN

sources

  1. Iovance Biotherapeutics 3Q 2026: Revenue $121.47M, EPS ($0.05) — 10-Q Summary — TradingView, 5 November 2026 at 14:21 UTC
  2. N-able 3Q 2026: Revenue $137.45M, EPS ($0.02) — 10-Q Summary — TradingView, 5 November 2026 at 14:21 UTC
  3. Silgan 3Q 2026: Revenue $2.04B, EPS $0.99 — 10-Q Summary — TradingView, 5 November 2026 at 14:21 UTC
  4. Viatris 3Q 2026: Revenue $3.75B, EPS ($0.28) — 10-Q Summary — TradingView, 5 November 2026 at 14:31 UTC
  5. Lipocine 3Q 2026: Revenue $2.29M, EPS ($0.08) — 10-Q Summary — TradingView, 5 November 2026 at 14:41 UTC
  6. Goodyear 3Q 2026: Revenue $4.54B, EPS ($0.82) — 10-Q Summary — TradingView, 5 November 2026 at 15:21 UTC
  7. Tronox 3Q 2026: Revenue $827M, EPS ($0.34) — 10-Q Summary — TradingView, 5 November 2026 at 15:21 UTC
  8. Lemonade 3Q 2026: Revenue $336.1M, EPS ($0.56) — 10-Q Summary — TradingView, 5 November 2026 at 15:41 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗